Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-agent Idelalisib for Previously Treated Low-grade Lymphoma: A Phase 1/2 Study of Safety, Efficacy, and Flow-cytometric Assessment of Tumor-cell Signaling Events

NCT01306643 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01306643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01306643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-agent Idelalisib for Previously Treated Low-grade Lymphoma: A Phase 1/2 Study of Safety, Efficacy, and Flow-cytometric Assessment of Tumor-cell Signaling Events
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2011
Completion date
August 31, 2015
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, indolent non-hodgkin's lymphoma, marginal zone lymphoma, small lymphocytic lymphoma